Navigation Links
Genome Scan Gives Man Insight Into Future Health Risks
Date:4/30/2010

'We're at the dawn of a new age in genomics,' researcher says

FRIDAY, April 30 (HealthDay News) -- Stephen Quake, a Stanford University professor of bioengineering, now has a very good sense of his own genetic destiny.

Quake's DNA was the focus of the first completely mapped genome of a healthy person aimed at predicting future health risks. The scan was conducted by a team of Stanford researchers and cost about $50,000. The researchers say they can now predict Quake's risk for dozens of diseases and how he might respond to a number of widely used medicines.

This type of individualized risk report could become common within the next decade and may become much cheaper, according to the Stanford team.

"The $1,000 genome [test] is coming fast. The challenge lies in knowing what to do with all that information. We've focused on establishing priorities that will be most helpful when a patient and a physician are sitting together looking at the computer screen," Euan Ashley, an assistant professor of medicine, said in a university news release.

Those priorities include assessing how a person's activity levels, weight, diet and other lifestyle habits combine with his or her genetic risk for, or protection against, health problems such as diabetes or heart attack. It's also important to determine if a certain medication is likely to benefit the patient or cause harmful side effects.

"We're at the dawn of a new age in genomics," Quake said. "Information like this will enable doctors to deliver personalized health care like never before. Patients at risk for certain diseases will be able to receive closer monitoring and more frequent testing, while those who are at lower risk will be spared unnecessary tests. This will have important economic benefits as well, because it improves the efficiency of medicine."

In mapping Quake's genome, researchers designed an algorithm that overlaid his genetic data, on top of what was already known about his health risks based on his age and gender. The analysis focused on 55 conditions, ranging from diabetes and obesity to gum disease and schizophrenia.

The analysis revealed that Quake has a 23 percent risk of prostate cancer and a 1.4 percent risk of Alzheimer's disease. He also has a more than 50 percent chance of developing obesity, type 2 diabetes and coronary artery disease.

However, lifestyle habits can have a strong impact on genetic risk factors, the experts noted.

Speaking to the Associated Press, Quake said that a personal genome reading might not be a great idea for everyone. "All you hear about when they talk about your genome is ways you're going to die and get sick. It doesn't tell you you're going to be happy or a great athlete," he noted. "If you're a worrier, this is not for you."

And another expert unconnected to the research worried about privacy issues. "The genie is now out of the bottle," Nilesh Samani, of the department of cardiovascular sciences at the University of Leicester, told the AP. "We need to think carefully about whether we need laws to prevent genetic information from getting into the wrong hands."

The research was funded by the U.S. National Institute of General Medical Sciences, and the National Heart, Lung and Blood Institute, among others. All the researchers have either financial ties to, or are involved with, genetic testing firms, drug makers or other health industry companies.

The research was released online April 29 and will be published in the May 1 print issue of The Lancet.

More information

The U.S. National Human Genome Research Institute has more about genetic testing.



-- Robert Preidt



SOURCE: Stanford University, news release, April 29, 2010; April 29, 2010, Associated Press


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Patients whole genome reveals risk of diseases and adverse drug responses
2. Genome Sequencing Reveals How Breast Cancer Spreads
3. Human Genome Turns 10
4. Medicines Future Could Lie in Each Patients Genome
5. Entire Family Genome Sequenced for First Time
6. Mayo oral cancer study shows full tumor genome
7. Johns Hopkins scientists develop personalized blood tests for cancer using whole genome sequencing
8. GenomeQuest Hosts Seminar Focused On Web-based Searching for Patent Information Across Global Sequence Databases
9. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
10. Genome Mapped for Type 2 Diabetes
11. Scientists map out regulatory regions of genome, hot spots for diabetes genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... ... Houma, LA, celebrates the beginning of a new charity campaign. As part of ... Appointed Special Advocates (CASA). In the belief that children deserve a voice, and ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... If you ... much to handle, you are not alone. According to the Center for Disease Control ... disease, stroke, type 2 diabetes and certain types of cancer, some of the leading ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... program serving the greater Venice, FL area, has initiated a fundraiser for a ... car accident just four days after Christmas. To support this beautiful child who ...
(Date:2/8/2016)... ... February 08, 2016 , ... Eating disorders and post-traumatic ... of women and men with eating disorders report a history of trauma, research ... development of an eating disorder. , At the 2016 iaedp Symposium, the ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Association of ... AHCC and the Home Health and Hospice ICD-10 Transition Workgroup are working closely ... coding guidance and clarifications, to address concerns over the use of 'A' as ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Feb. 8, 2016  HemaFlo Therapeutics, Inc. announced today that ... US Patent Number 9,119,880 covering the use of NephroFlow to ... , PhD, HemaFlo,s founder, said, "We are pleased to secure ... Dale Peterson , PhD, HemaFlo,s founder, said, "We are ... --> Dale Peterson , PhD, HemaFlo,s ...
(Date:2/8/2016)... Feb. 8, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... editing, announced that the U.S. Food and Drug ... Drug (IND) application for SB-318, a single treatment ... Mucopolysaccharidosis Type I (MPS I). The SB-318 IND ... initiate a Phase 1/2 clinical study (SB-318-1502) designed ...
(Date:2/8/2016)... , 8. Februar 2016  LivaNova, ... heute eine Infografik mit dem Titel „Epilepsy ... Welt), mit der der Krankheit gegenüber ein ... dazu ermutigen soll, Medikamentenresistenz bei Epilepsie auf ... allgemeinen Diskussion zu machen. Mithilfe der neuen ...
Breaking Medicine Technology: